Pacific Biosciences of California, Inc. (NASDAQ:PACB – Get Rating) insider Christian O. Henry sold 91,307 shares of the stock in a transaction dated Thursday, September 15th. The stock was sold at an average price of $5.78, for a total transaction of $527,754.46. Following the sale, the insider now directly owns 688,551 shares in the company, valued at $3,979,824.78. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
Pacific Biosciences of California Stock Up 1.2 %
PACB stock opened at $6.09 on Tuesday. The company has a market cap of $1.37 billion, a price-to-earnings ratio of -6.62 and a beta of 1.33. The company has a current ratio of 11.50, a quick ratio of 11.07 and a debt-to-equity ratio of 1.31. Pacific Biosciences of California, Inc. has a 12 month low of $3.85 and a 12 month high of $31.10. The firm has a 50-day moving average of $5.84 and a two-hundred day moving average of $6.50.
Get Pacific Biosciences of California alerts:Pacific Biosciences of California (NASDAQ:PACB – Get Rating) last released its quarterly earnings data on Wednesday, August 3rd. The biotechnology company reported ($0.32) EPS for the quarter, beating analysts' consensus estimates of ($0.34) by $0.02. Pacific Biosciences of California had a negative net margin of 147.39% and a negative return on equity of 35.76%. During the same period in the prior year, the business posted ($0.21) earnings per share. As a group, analysts forecast that Pacific Biosciences of California, Inc. will post -1.37 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
A number of research analysts recently weighed in on the stock. Canaccord Genuity Group decreased their price target on shares of Pacific Biosciences of California from $17.00 to $14.00 and set a "buy" rating on the stock in a research note on Friday, August 5th. Cowen decreased their price target on shares of Pacific Biosciences of California to $8.00 in a research note on Tuesday, August 9th. Finally, Piper Sandler decreased their price target on shares of Pacific Biosciences of California from $7.50 to $6.00 in a research note on Sunday, August 21st. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, Pacific Biosciences of California presently has a consensus rating of "Moderate Buy" and an average target price of $22.00.Institutional Trading of Pacific Biosciences of California
Hedge funds and other institutional investors have recently made changes to their positions in the company. KRS Capital Management LLC acquired a new stake in shares of Pacific Biosciences of California during the 4th quarter worth approximately $71,000. Harbor Investment Advisory LLC increased its holdings in shares of Pacific Biosciences of California by 94.5% during the 1st quarter. Harbor Investment Advisory LLC now owns 3,636 shares of the biotechnology company's stock worth $33,000 after buying an additional 1,767 shares during the last quarter. Captrust Financial Advisors increased its holdings in shares of Pacific Biosciences of California by 217.2% during the 2nd quarter. Captrust Financial Advisors now owns 6,163 shares of the biotechnology company's stock worth $27,000 after buying an additional 4,220 shares during the last quarter. Vienna Asset Management LLC acquired a new stake in shares of Pacific Biosciences of California during the 4th quarter worth approximately $151,000. Finally, Versor Investments LP acquired a new stake in shares of Pacific Biosciences of California during the 2nd quarter worth approximately $44,000.
About Pacific Biosciences of California
(Get Rating)
Pacific Biosciences of California, Inc designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases.
Further Reading
- Get a free copy of the StockNews.com research report on Pacific Biosciences of California (PACB)
- Oracle's Short-Term Pain Could Be Your Long-Term Gain
- Lucid is Looking Like a Clear EV Winner
- Still Lovin' It: Investors Keep Visiting McDonald's
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
Receive News & Ratings for Pacific Biosciences of California Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacific Biosciences of California and related companies with MarketBeat.com's FREE daily email newsletter.